+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022

  • PDF Icon

    Report

  • 700 Pages
  • December 2022
  • Region: Global
  • CurrentPartnering
  • ID: 2563605
The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2015, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

  • In-depth understanding of monoclonal antibodies deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements
  • Comprehensive access to over 1100 actual monoclonal antibodies deals entered into by the world’s biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 includes:

  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1100 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2015
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2015

In Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive access to available deals and contract documents for over 1100 monoclonal antibody deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
2.6.1 Monoclonal antibody partnering headline values
2.6.2 Monoclonal antibody deal upfront payments
2.6.3 Monoclonal antibody deal milestone payments
2.6.4 Monoclonal antibody royalty rates
Chapter 3 - Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value
Chapter 4 - Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles
Chapter 5 - Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory
Chapter 6 - Monoclonal antibody dealmaking by technology type
  • Monoclonal antibodies
  • Chimeric mAb
  • Humanized mAb
  • Human mAb
  • Murine mAb
Appendices
Appendix 1 - Monoclonal antibody deals by company A-Z
Appendix 2 - Monoclonal antibody deals by stage of development
Appendix 3 - Monoclonal antibody deals by deal type
Appendix 4 - Monoclonal antibody deals by therapy area
Appendix 5 - Appendix 6 - Table of figures
Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2015
Figure 3: Active monoclonal antibody dealmaking activity since 2015
Figure 4: Monoclonal antibody partnering by deal type since 2015
Figure 5: Monoclonal antibody partnering by disease type since 2015
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2015
Figure 11: Most active monoclonal antibody dealmakers since 2015

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3D Medicines
  • 3rd People’s Hospital of Shenzhen
  • 3SBio
  • 4D Pharma
  • 9 Meters Biopharma
  • A*STAR Bioprocessing Technology Institute
  • Abbvie
  • Abcam
  • AbCellera
  • AbCheck
  • AbClon
  • Abdul Latif Jameel Health
  • ABL Bio
  • Ablexis
  • Ablynx
  • Abmuno Therapeutics
  • Aboundbio
  • Abpro
  • Ab Studio
  • Abveris
  • Abzena
  • Acceleron Pharma
  • Accord Healthcare
  • Acerta Pharma
  • Achaogen
  • Acticor Biotech
  • Adagene
  • Adagio Therapeutics
  • Adaptimmune
  • Adaptive Biotechnologies
  • Adimab
  • Adium Pharma
  • Adlai Nortye
  • Aduro BioTech
  • Advanced BioScience Laboratories
  • Advaxis
  • Aeglea BioTherapeutics
  • Aevi Genomic Medicine
  • AffaMed Therapeutics
  • Affimed Therapeutics
  • Affinita Biotech
  • AGC Biologics
  • Agenus Bio
  • Agilvax
  • Aimmune Therapeutics
  • Ajinomoto
  • Ajinomoto Bio-Pharma Services
  • Akeso Biopharma
  • Alder Biopharmaceuticals
  • Alector
  • Alexion Pharmaceuticals
  • Alfasigma
  • AlivaMab Discovery Services
  • Allergan
  • Alligator Bioscience
  • Allinaire Therapeutic
  • Alloy Therapeutics
  • Almac Group
  • Almirall
  • Alphamab Biopharmaceuticals
  • Alpine Immune Sciences
  • Alvogen
  • Alvotech
  • ALX Oncology
  • Alzheimer's Drug Discovery Foundation
  • Ambrx
  • Amgen
  • Amneal Pharmaceuticals
  • Amplyx Pharmaceuticals
  • AnGes MG
  • Angios
  • Antengene
  • Antidote Therapeutics
  • Antigen Express
  • Antitope
  • Apceth
  • Aperion Biologics
  • Apexigen
  • Applied BioMath
  • APRINOIA Therapeutics
  • Aptevo Therapeutics
  • Aqualung Therapeutics
  • Arch Oncology
  • Arcus Biosciences
  • arGEN-X
  • argenx
  • Aridis Pharmaceuticals
  • ARMO Biosciences
  • Array Biopharma
  • Arsanis Biosciences
  • Ascenion
  • Ascentage Pharma
  • Asieris MediTech
  • Aslan Pharma
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atara Biotherapeutics
  • Athenex
  • Atlab Pharma
  • Atlante Biotech
  • Atlas Antibodies
  • ATP
  • Atreca
  • ATUM
  • aTyr Pharma
  • Augmenta
  • Aulos Bioscience
  • AvantGen
  • Avantor
  • AVEO Oncology
  • Avid Bioservices
  • Avidity Biosciences
  • Axantia
  • Aytu BioPharma
  • Back-A-Line
  • Banner Alzheimer's Institute
  • Basilea Pharmaceutica
  • Bausch & Lomb
  • Bavarian Nordic
  • Baxalta
  • Bayer
  • Baylor Institute for Immunology Research
  • BB100
  • BeiGene
  • Beijing InnoCare Pharma
  • BerGenBio
  • Berkeley Lights
  • Betta Pharmaceuticals
  • BHR Pharma
  • Bill and Melinda Gates Foundation
  • Binex
  • Bio-Manguinhos/Fiocruz
  • Bio-Thera Solutions
  • BioArctic Neuroscience
  • BioAtla
  • Biocare Medical
  • Biocon
  • Biocytogen
  • Biodesix
  • Bioeq IP
  • Bio Farma
  • Biogen
  • BioInvent
  • BiolineRX
  • Biolojic Design
  • BioMarker Strategies
  • Biomedical Advanced Research and Development Authority
  • Biomm
  • Biomunex Pharmaceuticals
  • Bioncotech Therapeutics
  • Biond Biologics
  • BioNTech
  • BioRap Technologies
  • BiosanaPharma
  • Biosion
  • Biothera Pharmaceuticals
  • Biotools
  • BioVectra
  • BioXcel
  • Blackstone
  • BliNK Biomedical
  • BliNK Therapeutics
  • Bluebird Bio
  • BlueJay Therapeutics
  • Boehringer Ingelheim
  • Bolt Biotherapeutics
  • Boston Immune Technologies and Therapeutics
  • Bpifrance
  • BridgeBio Pharma
  • Brigham and Women's Hospital
  • Bright Peak Therapeutics
  • Brii Biosciences
  • Bristol-Myers Squibb

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...